Three firms reiterated ratings on Candel Therapeutics Inc (CADL) on November 13, 2026. Three bullish, zero neutral, zero bearish. No firm changed its rating.
| Firm | Rating | Tier |
|---|---|---|
| Canaccord Genuity | Buy | bullish |
| HC Wainwright & Co. | Buy | bullish |
| Stifel | Buy | bullish |
The past 90 days include five active firms, with five rating the stock bullish. 10 analysts set consensus price targets as of November 10, 2026, with a mean of $23.33, a median of $24.48 and a range of $15.15 to $30.45.
Consensus Q4 FY2026 EPS is -$0.38, with revenue at $0. The next earnings report is on March 10, 2027.
